<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434379</url>
  </required_header>
  <id_info>
    <org_study_id>YO40245</org_study_id>
    <secondary_id>2017-003691-31</secondary_id>
    <nct_id>NCT03434379</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma</brief_title>
  <acronym>IMbrave150</acronym>
  <official_title>A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of atezolizumab in combination with&#xD;
      bevacizumab compared with sorafenib in participants with locally advanced or metastatic&#xD;
      Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants will be randomized in a 2:1 ratio to one of the two treatment arms: Arm A&#xD;
      (experimental arm): Atezolizumab +bevacizumab; Arm B (control arm): Sorafenib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in the Global Population</measure>
    <time_frame>From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)</time_frame>
    <description>OS was defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in the China Population</measure>
    <time_frame>From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)</time_frame>
    <description>OS was defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS-IRF Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS-IRF Per HCC mRECIST in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP-IRF Per HCC mRECIST in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival by Baseline AFP in the Global Population</measure>
    <time_frame>From randomization to death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>OS was defined as the time from randomization to death from any cause. Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS-IRF Per RECIST v1.1 by Baseline AFP in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS-INV Per RECIST v1.1 by Baseline AFP in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the Global Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) in the Global Population</measure>
    <time_frame>Up to end of study (up to approximately 40 months)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population</measure>
    <time_frame>Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration (Cmin) of Atezolizumab in the Global Population</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population</measure>
    <time_frame>Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 30 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS-IRF Per HCC mRECIST in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP-IRF Per HCC mRECIST in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the China Population</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
    <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) in the China Population</measure>
    <time_frame>Up to end of study (up to approximately 40 months)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population</measure>
    <time_frame>Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration (Cmin) of Atezolizumab in the China Population</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population</measure>
    <time_frame>Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle</description>
    <arm_group_label>Atezolizumab + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)&#xD;
&#xD;
          -  No prior systemic therapy for HCC. Previous use of herbal therapies/traditional&#xD;
             Chinese medicines with anti-cancer activity included in the label is allowed, provided&#xD;
             that these medications are discontinued prior to randomization.&#xD;
&#xD;
          -  At least one measurable untreated lesion&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent&#xD;
&#xD;
          -  For men: agreement to remain abstinent&#xD;
&#xD;
          -  Child-Pugh class A&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography scan&#xD;
&#xD;
          -  Known active tuberculosis&#xD;
&#xD;
          -  History of malignancy other than HCC within 5 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment&#xD;
             or within at least 5 months after the last dose of atezolizumab, 6 months after the&#xD;
             last dose of bevacizumab, or 1 month after the last dose of sorafenib&#xD;
&#xD;
          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC&#xD;
&#xD;
          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or&#xD;
             high-risk for bleeding&#xD;
&#xD;
          -  A prior bleeding event due to esophageal and/or gastric varices within 6 months prior&#xD;
             to initiation of study treatment.&#xD;
&#xD;
          -  Moderate or severe ascites&#xD;
&#xD;
          -  History of hepatic encephalopathy&#xD;
&#xD;
          -  Co-infection of HBV and HCV&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)&#xD;
             metastases&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents&#xD;
&#xD;
          -  Inadequately controlled arterial hypertension&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy&#xD;
&#xD;
          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction&#xD;
             including sub-occlusive disease related to the underlying disease or requirement for&#xD;
             routine parenteral hydration&#xD;
&#xD;
          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
          -  Metastatic disease that involves major airways or blood vessels, or centrally located&#xD;
             mediastinal tumor masses&#xD;
&#xD;
          -  Local therapy to liver within 28 days prior to initiation of study treatment or&#xD;
             non-recovery from side effects of any such procedure&#xD;
&#xD;
          -  Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Josephs Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of California - San Diego; Cancer Center &amp; Dept of Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California</name>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University; Wash Uni. Sch. Of Med</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and ISAAC Perlmutter Cancer Center at NYU Langone.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D Anderson Cancer Center; Uni of Texas At Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Inst.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Glen Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <zip>132013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha City</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 900th Hospital of PLA joint service support force</name>
      <address>
        <city>Fuzhou</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Province Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Jinan Military Command of PLA</name>
      <address>
        <city>Jinan</city>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 81st Hospital of P.L.A.</name>
      <address>
        <city>Nanjing City</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai City</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. &amp; Tech</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc; Onkologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez;Gastro Enterologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De La Croix Rousse; Hepatologie Gastro Enterologie</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Timone Adultes; Gastro Enterologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hpital de l'Archet 2; service Hepato gastro enterologie</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle; Gastroenterologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre; Gastro Enterologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hpital d'Adultes; Service hpato-gastro-entrologie</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Gastro-Enterologie</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Virchow-Klinikum Charit Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf; I. Medizinische Klinik - Gastroenterologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover; Gastroenterologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universittsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog.</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Mainz; I. Medizinische Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hmatologie und Internistische Onkologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital; Dept. Of Haematology &amp; Oncology</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hosp; Dept. Of Clinical Onc</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Rummo; Oncologia Medica</name>
      <address>
        <city>Benevento</city>
        <state>Campania</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Luigi Gonzaga; Divisione Di Oncologia Medica</name>
      <address>
        <city>Orbassano</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Kosei General Hosopital</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga-ken Medical Centre Koseikan</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Musashino Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hosiptal</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skodowskiej-Curie - Pastwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnolskie Centrum Onkologii; Oddzia Onkologii Klinicznej i Chemioterapii</name>
      <address>
        <city>Wrocaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Center of Oncology N.N. Blokhin&quot;; Clinical Biotechnologies</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal; Servicio de Oncologa</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet; Servicio de Oncologia Medica</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital; Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>00704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Centre; Hematology &amp; Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital; Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>00112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; Dept of Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkou; Dept of Oncology</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital; Dept of Oncology</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King'S College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <results_first_submitted>August 16, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03434379/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03434379/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 117 sites in 17 countries: Australia, Canada, China, Czech Republic, Germany, Spain, France, United Kingdom, Hong Kong, Italy, Japan, Republic of Korea, Poland, Russian Federation, Singapore, Taiwan, United States.</recruitment_details>
      <pre_assignment_details>The total study population included 558 participants. The Global population included 501 participants. An additional 57 participants enrolled during the China Extension. The total China population included 137 Chinese participants from the Global population plus 57 participants from the China extension. 137 participants were part of the Global as well as China populations. Separate analyses were performed for the Global population and the China population in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib - Global</title>
          <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="P2">
          <title>Atezolizumab + Bevacizumab - Global</title>
          <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="P3">
          <title>Sorafenib - China</title>
          <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="P4">
          <title>Atezolizumab + Bevacizumab - China</title>
          <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Global Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On Study</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>China Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="61">n=43 Chinese participants from the sorafenib Global population are included in the China population.</participants>
                <participants group_id="P4" count="133">n=94 Chinese participants from the Atezolizumab + Bevacizumab Global population are included in the China population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="133"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population included 558 participants (All) with 501 in the Global population. An additional 57 participants enrolled in the China Extension. The China population included 137 Chinese participants from the Global population plus 57 participants from the China Extension. The Global population and China population were analyzed separately.</population>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib - All</title>
          <description>All participants either in the Global or China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="B2">
          <title>Atezolizumab + Bevacizumab - All</title>
          <description>All participants either in the Global or China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="375"/>
            <count group_id="B3" value="558"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The Global population included 501 participants. The China population included 57 participants enrolled during the China Extension plus 137 Chinese participants from the Global population.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Global</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="165"/>
                    <count group_id="B2" value="336"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="10.9"/>
                    <measurement group_id="B2" value="62.9" spread="11.9"/>
                    <measurement group_id="B3" value="63.4" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="12.7"/>
                    <measurement group_id="B2" value="55.3" spread="12.0"/>
                    <measurement group_id="B3" value="56.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The Global population included 501 participants. The China population included 57 participants enrolled during the China Extension plus 137 Chinese participants from the Global population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Global</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="165"/>
                    <count group_id="B2" value="336"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>The Global population included 501 participants. The China population included 57 participants enrolled during the China Extension plus 137 Chinese participants from the Global population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Global</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="165"/>
                    <count group_id="B2" value="336"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="455"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>The Global population included 501 participants. The China population included 57 participants enrolled during the China Extension plus 137 Chinese participants from the Global population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Global</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="165"/>
                    <count group_id="B2" value="336"/>
                    <count group_id="B3" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                    <count group_id="B2" value="133"/>
                    <count group_id="B3" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in the Global Population</title>
        <description>OS was defined as the time from randomization to death from any cause.</description>
        <time_frame>From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the Global Population</title>
          <description>OS was defined as the time from randomization to death from any cause.</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At CCOD 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.24" lower_limit="10.41" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At CCOD 30 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.40" lower_limit="11.37" upper_limit="16.85"/>
                    <measurement group_id="O2" value="19.22" lower_limit="17.02" upper_limit="23.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At CCOD 18 months; Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein (AFP: &lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At CCOD 30 months; Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline alpha-fetoprotein (AFP: &lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="3.98" upper_limit="5.55"/>
                    <measurement group_id="O2" value="6.83" lower_limit="5.75" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in the China Population</title>
        <description>OS was defined as the time from randomization to death from any cause.</description>
        <time_frame>From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the China Population</title>
          <description>OS was defined as the time from randomization to death from any cause.</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At CCOD 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" lower_limit="6.74" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="13.50" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At CCOD 30 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" lower_limit="6.74" upper_limit="16.07"/>
                    <measurement group_id="O2" value="24.05" lower_limit="17.12" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At CCOD 18 months; Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At CCOD 30 months; Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PFS-IRF Per RECIST v1.1 in the China Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-IRF Per RECIST v1.1 in the China Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease (PD) or death from any cause whichever occurs first as determined by an IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.56" upper_limit="4.76"/>
                    <measurement group_id="O2" value="5.72" lower_limit="4.17" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the Global Population</title>
        <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the Global Population</title>
          <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="7.35" upper_limit="18.03"/>
                    <measurement group_id="O2" value="27.3" lower_limit="22.54" upper_limit="32.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>5.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the Global Population</title>
        <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the Global Population</title>
          <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="8.42" upper_limit="19.60"/>
                    <measurement group_id="O2" value="33.2" lower_limit="28.13" upper_limit="38.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.02</ci_lower_limit>
            <ci_upper_limit>5.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the Global Population</title>
        <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the Global Population</title>
          <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.54" upper_limit="10.16"/>
                    <measurement group_id="O2" value="25.6" lower_limit="21.01" upper_limit="30.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.99</ci_lower_limit>
            <ci_upper_limit>12.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the Global Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the Global Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" lower_limit="4.67" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the Global Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the Global Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" lower_limit="4.86" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the Global Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the Global Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included Global participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5.39" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="13.08" lower_limit="13.08" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4187</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS-IRF Per HCC mRECIST in the Global Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-IRF Per HCC mRECIST in the Global Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.98" upper_limit="5.45"/>
                    <measurement group_id="O2" value="6.83" lower_limit="5.72" upper_limit="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the Global Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the Global Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.76" upper_limit="4.17"/>
                    <measurement group_id="O2" value="7.06" lower_limit="5.68" upper_limit="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the Global Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the Global Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" lower_limit="4.21" upper_limit="7.72"/>
                    <measurement group_id="O2" value="8.57" lower_limit="6.83" upper_limit="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0105</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTP-IRF Per HCC mRECIST in the Global Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>TTP-IRF Per HCC mRECIST in the Global Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="4.21" upper_limit="7.69"/>
                    <measurement group_id="O2" value="8.28" lower_limit="6.80" upper_limit="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the Global Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the Global Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="2.83" upper_limit="4.30"/>
                    <measurement group_id="O2" value="8.54" lower_limit="6.93" upper_limit="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival by Baseline AFP in the Global Population</title>
        <description>OS was defined as the time from randomization to death from any cause. Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
        <time_frame>From randomization to death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival by Baseline AFP in the Global Population</title>
          <description>OS was defined as the time from randomization to death from any cause. Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AFP &lt;400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.93" lower_limit="11.73" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP &gt;/=400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.10" lower_limit="5.75" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="12.78" lower_limit="10.15" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP &lt;400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP &gt;/= 400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0879</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS-IRF Per RECIST v1.1 by Baseline AFP in the Global Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-IRF Per RECIST v1.1 by Baseline AFP in the Global Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AFP &lt;400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" lower_limit="4.01" upper_limit="6.21"/>
                    <measurement group_id="O2" value="8.28" lower_limit="6.83" upper_limit="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP &gt;/=400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="2.76" upper_limit="5.26"/>
                    <measurement group_id="O2" value="5.19" lower_limit="3.94" upper_limit="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP&lt;400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP &gt;/=400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2159</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS-INV Per RECIST v1.1 by Baseline AFP in the Global Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-INV Per RECIST v1.1 by Baseline AFP in the Global Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm). Subpopulations with baseline AFP &lt;400 ng/mL and AFP&gt;/= 400 ng/mL were analyzed.</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AFP &lt;400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="2.79" upper_limit="5.62"/>
                    <measurement group_id="O2" value="8.41" lower_limit="7.06" upper_limit="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFP &gt;/=400 ng/mL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="1.58" upper_limit="3.98"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.17" upper_limit="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP &lt;400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AFP &gt;/=400 ng/mL and stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration (TTD) in the Global Population</title>
        <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - Global</title>
            <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration (TTD) in the Global Population</title>
          <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
          <population>Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="3.48" upper_limit="6.24"/>
                    <measurement group_id="O2" value="13.14" lower_limit="9.69" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2.20" upper_limit="5.98"/>
                    <measurement group_id="O2" value="9.13" lower_limit="6.51" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHS/QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="3.02" upper_limit="6.97"/>
                    <measurement group_id="O2" value="11.24" lower_limit="5.98" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Functioning: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GHS/QoL: Stratified by geographic region (Asia [excluding Japan] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs) in the Global Population</title>
        <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Up to end of study (up to approximately 40 months)</time_frame>
        <posting_date>06/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population</title>
        <time_frame>Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)</time_frame>
        <population>The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax) of Atezolizumab at Cycle 1 in the Global Population</title>
          <population>The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
          <units>micrograms/milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Serum Concentration (Cmin) of Atezolizumab in the Global Population</title>
        <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)</time_frame>
        <population>The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Cmin) of Atezolizumab in the Global Population</title>
          <population>The Global pharmacokinetic (PK)-evaluable population was defined as all participants in the Global population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 3, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 4, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" spread="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 8, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 12, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 16, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population</title>
        <time_frame>Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 30 months)</time_frame>
        <population>The Global ADA-evaluable population was defined as all participants in the Global population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - Global</title>
            <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the Global Population</title>
          <population>The Global ADA-evaluable population was defined as all participants in the Global population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the China Population</title>
        <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per RECIST v1.1 in the China Population</title>
          <description>ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1.85" upper_limit="16.20"/>
                    <measurement group_id="O2" value="24.6" lower_limit="17.49" upper_limit="32.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>13.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the China Population</title>
        <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate by IRF-Assessment (ORR-IRF) Per Hepatocellular Carcinoma (HCC) Modified RECIST (mRECIST) in the China Population</title>
          <description>ORR was defined as the percentage of participants with CR or PR as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver measuring only the residual vital tumor mass in the liver. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.81" upper_limit="18.68"/>
                    <measurement group_id="O2" value="29.7" lower_limit="21.94" upper_limit="38.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>12.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the China Population</title>
        <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the China Population</title>
          <description>ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR</description>
          <population>China ITT population with measurable disease at baseline consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="1.03" upper_limit="13.71"/>
                    <measurement group_id="O2" value="21.1" lower_limit="14.47" upper_limit="28.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>17.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the China Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the China Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="4.86" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="8.15" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4581</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the China Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by IRF Assessment (DOR-IRF) Per HCC mRECIST in the China Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="4.47" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="8.15" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0100</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Lower limit: &lt;0.01</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the China Population</title>
        <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
        <time_frame>Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response by Investigator Assessment (DOR-INV) Per RECIST v1.1 in the China Population</title>
          <description>DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 mm.</description>
          <population>The analysis population included China participants with a confirmed response (CR or PR).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="4.17" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3477</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS-IRF Per HCC mRECIST in the China Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-IRF Per HCC mRECIST in the China Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.56" upper_limit="4.76"/>
                    <measurement group_id="O2" value="5.72" lower_limit="4.17" upper_limit="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0103</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the China Population</title>
        <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS by Investigator Assessment (PFS-INV) Per RECIST v1.1 in the China Population</title>
          <description>PFS was defined as the time from randomization to the first occurrence of progressive disease or death from any cause whichever occurs first as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.73" upper_limit="3.98"/>
                    <measurement group_id="O2" value="5.55" lower_limit="4.21" upper_limit="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the China Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) by IRF Assessment (TTP-IRF) Per RECIST v1.1 in the China Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="2.76" upper_limit="10.15"/>
                    <measurement group_id="O2" value="7.00" lower_limit="5.45" upper_limit="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0927</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTP-IRF Per HCC mRECIST in the China Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>TTP-IRF Per HCC mRECIST in the China Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the IRF according to HCC mRECIST. HCC mRECIST differentiates between vital tumor and necrotic areas in the liver, measuring only the residual vital tumor mass in the liver. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" lower_limit="2.76" upper_limit="10.15"/>
                    <measurement group_id="O2" value="7.00" lower_limit="5.45" upper_limit="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0861</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the China Population</title>
        <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>TTP by Investigator Assessment (TTP-INV) Per RECIST v1.1 in the China Population</title>
          <description>Time to progression was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator according to RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of &gt;/= 5 millimeters (mm).</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.79" upper_limit="4.17"/>
                    <measurement group_id="O2" value="6.83" lower_limit="5.32" upper_limit="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration (TTD) in the China Population</title>
        <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
        <time_frame>Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)</time_frame>
        <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib - China</title>
            <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration (TTD) in the China Population</title>
          <description>TTD was defined as the time from randomization to the first deterioration (decrease from baseline of &gt;/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.</description>
          <population>China ITT population consisted of all randomized participants in the China population, whether or not the participant had received the assigned study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" lower_limit="2.10" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="13.14" lower_limit="9.69" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="2.14" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="7.20" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHS/QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="1.48" upper_limit="9.82"/>
                    <measurement group_id="O2" value="9.76" lower_limit="6.24" upper_limit="NA">NA = not estimable due to the limited number of events observed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Functioning: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2214</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GHS/QoL: Stratified by macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (&lt;400 vs. &gt;/= 400 ng/mL).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0135</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs) in the China Population</title>
        <description>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Up to end of study (up to approximately 40 months)</time_frame>
        <posting_date>06/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population</title>
        <time_frame>Post-dose on Day 1 of Cycle 1 (cycle length = 21 days)</time_frame>
        <population>The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax) of Atezolizumab in the China Population</title>
          <population>The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Serum Concentration (Cmin) of Atezolizumab in the China Population</title>
        <time_frame>Pre-dose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length = 21 days)</time_frame>
        <population>The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Cmin) of Atezolizumab in the China Population</title>
          <population>The China PK-evaluable population was defined as all participants in the China population who received any dose of study treatment and who had at least one post-baseline PK sample available.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Cycle 2, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" spread="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 3, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 4, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 8, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" spread="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 12, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201" spread="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Cycle 16, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" spread="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population</title>
        <time_frame>Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)</time_frame>
        <population>The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab + Bevacizumab - China</title>
            <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population</title>
          <population>The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to clinical cut off date (CCOD) of 31 August, 2020 (up to approximately 30 months)</time_frame>
      <desc>All-cause mortality is reported for deaths that occurred during the study based on the ITT population, which included all randomized participants. Serious and other adverse events were reported based on the safety population, which included all randomized participants who received any amount of study drug with participants grouped according to the treatment the participant actually received. Global and China extension periods were analyzed separately.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib - Global</title>
          <description>Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="E2">
          <title>Atezolizumab + Bevacizumab - Global</title>
          <description>Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="E3">
          <title>Sorafenib - China</title>
          <description>Participants in the China population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
        <group group_id="E4">
          <title>Atezolizumab + Bevacizumab - China</title>
          <description>Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="329"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemoperitoneum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Burkholderia pseudomallei infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Herpes simplex encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Granulocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Autoimmune arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Tumour rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>VIth nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="329"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E2" events="48" subjects_affected="35" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E4" events="38" subjects_affected="25" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="31" subjects_affected="20" subjects_at_risk="329"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="30" subjects_affected="18" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="329"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="19" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="44" subjects_affected="31" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="41" subjects_affected="22" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="329"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E2" events="56" subjects_affected="46" subjects_at_risk="329"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E4" events="22" subjects_affected="18" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="329"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E2" events="60" subjects_affected="55" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="105" subjects_affected="78" subjects_at_risk="156"/>
                <counts group_id="E2" events="98" subjects_affected="67" subjects_at_risk="329"/>
                <counts group_id="E3" events="36" subjects_affected="26" subjects_at_risk="58"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E2" events="62" subjects_affected="48" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="21" subjects_affected="17" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E2" events="49" subjects_affected="34" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="25" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="156"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E2" events="88" subjects_affected="73" subjects_at_risk="329"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" events="41" subjects_affected="35" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" events="82" subjects_affected="58" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="30" subjects_affected="22" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="39" subjects_affected="33" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E2" events="74" subjects_affected="53" subjects_at_risk="329"/>
                <counts group_id="E3" events="18" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E4" events="48" subjects_affected="29" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E2" events="110" subjects_affected="73" subjects_at_risk="329"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="58"/>
                <counts group_id="E4" events="73" subjects_affected="39" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="41" subjects_affected="31" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="26" subjects_affected="19" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="156"/>
                <counts group_id="E2" events="99" subjects_affected="56" subjects_at_risk="329"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E4" events="71" subjects_affected="31" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="156"/>
                <counts group_id="E2" events="65" subjects_affected="45" subjects_at_risk="329"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E4" events="46" subjects_affected="27" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" events="50" subjects_affected="46" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E2" events="54" subjects_affected="18" subjects_at_risk="329"/>
                <counts group_id="E3" events="14" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E4" events="61" subjects_affected="20" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="24" subjects_affected="12" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="33" subjects_affected="14" subjects_at_risk="329"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="43" subjects_affected="16" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="50" subjects_affected="39" subjects_at_risk="156"/>
                <counts group_id="E2" events="72" subjects_affected="65" subjects_at_risk="329"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="34" subjects_affected="21" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="26" subjects_affected="13" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="44" subjects_affected="37" subjects_at_risk="329"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="36" subjects_affected="28" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="329"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="329"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="329"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="329"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="329"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="329"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" events="163" subjects_affected="100" subjects_at_risk="329"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="114" subjects_affected="66" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cylindruria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="19" subjects_affected="7" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="20" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="329"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" events="53" subjects_affected="46" subjects_at_risk="329"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" events="44" subjects_affected="36" subjects_at_risk="329"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="329"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="156"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="329"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="81" subjects_affected="75" subjects_at_risk="156"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="329"/>
                <counts group_id="E3" events="39" subjects_affected="33" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E2" events="92" subjects_affected="70" subjects_at_risk="329"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="27" subjects_affected="23" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E2" events="49" subjects_affected="45" subjects_at_risk="329"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="329"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="43" subjects_affected="38" subjects_at_risk="156"/>
                <counts group_id="E2" events="180" subjects_affected="114" subjects_at_risk="329"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E4" events="80" subjects_affected="51" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

